NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has increased by 46.1% and is now trading at $15.50.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Accelerate Diagnostics.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to analyst estimates of $2.40 million. Accelerate Diagnostics had a negative net margin of 845.43% and a negative return on equity of 5,681.44%.
View Accelerate Diagnostics' earnings history.

4 equities research analysts have issued 1-year price objectives for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Accelerate Diagnostics' stock price to reach $17.25 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics.

Press coverage about AXDX stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Accelerate Diagnostics.

Accelerate Diagnostics saw a decrease in short interest in July. As of July 31st, there was short interest totaling 15,760,000 shares, a decrease of 8.9% from the July 15th total of 17,300,000 shares. Based on an average trading volume of 497,200 shares, the days-to-cover ratio is presently 31.7 days. Approximately 56.3% of the shares of the stock are short sold.
View Accelerate Diagnostics' Short Interest.

Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannell Peter B & Co. Inc. (2.02%), Chicago Capital LLC (1.37%), UBS Group AG (0.15%), Swiss National Bank (0.12%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.07%) and New York State Common Retirement Fund (0.05%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and UBS Group AG.
View insider buying and selling activity for Accelerate Diagnostics.

AXDX stock was purchased by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc., Russell Investments Group Ltd., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., SG Americas Securities LLC, Principal Financial Group Inc., Virtu Financial LLC, Swiss National Bank, and New York State Common Retirement Fund. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $15.50.

Accelerate Diagnostics has a market capitalization of $856.69 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]